PIQL.F Stock Overview

Operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, India, and South East Asia. More details

PIQL.F fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Risk Analysis

Has less than 1 year of cash runway

Shares are highly illiquid

Earnings have declined by 26.8% per year over past 5 years

Does not have meaningful revenue (A$3M)

+ 1 more risk

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Proteomics International Laboratories Ltd Competitors

Harvard Bioscience

NasdaqGM:HBIO

US$27.9m

Bioqual

OTCPK:BIOQ

US$53.7m

International Isotopes

OTCPK:INIS

US$23.4m

Inotiv

NasdaqCM:NOTV

US$88.9m

Price History & Performance

Summary of share price highs, lows and changes for Proteomics International Laboratories
Historical stock prices
Current Share Price	AU$0.31
52 Week High	AU$0.31
52 Week Low	AU$0.31
Beta	0.35
1 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	0%

Recent updates

Shareholder Returns

	PIQL.F	US Life Sciences	US Market
7D	0%	-2.2%	-2.2%
1Y	n/a	-19.2%	9.5%

Return vs Industry: Insufficient data to determine how PIQL.F performed against the US Life Sciences industry.

Return vs Market: Insufficient data to determine how PIQL.F performed against the US Market.

Price Volatility

Is PIQL.F's price volatile compared to industry and market?
PIQL.F volatility
PIQL.F Average Weekly Movement	n/a
Life Sciences Industry Average Movement	9.6%
Market Average Movement	6.4%
10% most volatile stocks in US Market	17.4%
10% least volatile stocks in US Market	3.4%

Stable Share Price: PIQL.F's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine PIQL.F's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2001	n/a	Richard Lipscombe	www.proteomics.com.au

Proteomics International Laboratories Ltd operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, India, and South East Asia. It provides PromarkerD, a protein-based diagnostic blood test to predict diabetic kidney disease (DKD). The company’s products under development include PromarkerEndo, which has completed clinical validation phase for endometriosis diagnosis; PromarkerEso, that has completed clinical validation trials for esophageal cancer diagnosis; and OxiDx (2-tag), which has completed clinical validation phase for oxidative stress treatment.

Proteomics International Laboratories Ltd Fundamentals Summary

How do Proteomics International Laboratories's earnings and revenue compare to its market cap?
PIQL.F fundamental statistics
Market cap	US$40.20m
Earnings (TTM)	-US$4.50m
Revenue (TTM)	US$2.21m

18.2x

P/S Ratio

-8.9x

P/E Ratio

Is PIQL.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PIQL.F income statement (TTM)
Revenue	AU$3.50m
Cost of Revenue	AU$2.04m
Gross Profit	AU$1.46m
Other Expenses	AU$8.57m
Earnings	-AU$7.11m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.054
Gross Margin	41.64%
Net Profit Margin	-203.39%
Debt/Equity Ratio	0%

How did PIQL.F perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/03/15 06:43
End of Day Share Price	2025/01/16 00:00
Earnings	2024/12/31
Annual Earnings	2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Proteomics International Laboratories Ltd is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Iain Wilkie	Morgans Financial Limited

Proteomics International Laboratories OTCPK:PIQL.F Stock Report